Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2011-04-05
2011-04-05
Zara, Jane (Department: 1635)
Chemistry: molecular biology and microbiology
Vector, per se
C435S006120, C435S091100, C435S091310, C435S455000, C536S023100, C536S024310, C536S024500
Reexamination Certificate
active
07919309
ABSTRACT:
In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. The methods can be used to express double stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that. In another aspect the invention provides methods for treating patients having suffering from infection, particularly infection with HIV.
REFERENCES:
patent: 5258289 (1993-11-01), Davis et al.
patent: 5650309 (1997-07-01), Wong-Stall et al.
patent: 5859310 (1999-01-01), Bujard et al.
patent: 5883081 (1999-03-01), Kraus et al.
patent: 5939538 (1999-08-01), Leavitt et al.
patent: 6022962 (2000-02-01), Chowrira et al.
patent: 6060317 (2000-05-01), Malech
patent: 6074836 (2000-06-01), Bordignon et al.
patent: 6096538 (2000-08-01), Kingsman et al.
patent: 6100087 (2000-08-01), Rossi et al.
patent: 6218186 (2001-04-01), Choi et al.
patent: 6255071 (2001-07-01), Beach et al.
patent: 6274788 (2001-08-01), Kumar et al.
patent: 6312956 (2001-11-01), Lane
patent: 6482618 (2002-11-01), Mueller et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6566083 (2003-05-01), Thastrup et al.
patent: 6635472 (2003-10-01), Lauermann
patent: 6664107 (2003-12-01), Mak et al.
patent: 2003/0084471 (2003-05-01), Beach et al.
patent: 2003/0124513 (2003-07-01), McSwiggen
patent: 2003/0143204 (2003-07-01), Lewis et al.
patent: 2003/0219823 (2003-11-01), Alsobrook et al.
patent: 2004/0072771 (2004-04-01), Symonds et al.
Arendt et al., “Vector Systems for the Delivery of Small Interfering RNAs: Managing the RISC” ChemBioChem 2003, 4, pp. 1129-1136.
Lieberman et al., “Interfering with disease: opportunities and roadblocks to harnessing RNA interference,” Trends in Molecular Medicine, vol. 9, No. 9 Sep. 2003, pp. 397-403.
Yang Shi, “Mammalian RNAi for the masses,” Trends in Genetics, vol. 19, No. 1, Jan. 2003, pp. 9-12.
Martinez, L.J., “Katy, bar the door! HIV entry inhibitors”, Research Initiative/Treatment Action Article, Jun. 2000, pp. 1-2.
“Scientists suggest new approaches for development of AIDS drugs and vaccines” National Cancer Insititute, Charity Wire, Article 01853, Jun. 21,1999, pp. 1-3.
“Pushing the Envelope” Howard Hughes Medical Institute (HHMI) News, Nov. 21, 1997, pp. 1-2.
“Mutant Gene Produces Strong Natural Resistance to HIV-1 Infection in 1 in 100 People”, University of Pennsylvania Health System, News and Periodicals, Aug. 8, 1996, pp. 1-3.
Shankar, Premlata, “RNAi-Mediated Inhibition of HIV-1 Replication in Primary Macrophages”, Biosino Genome, Presentation, Aug. 12, 2003, pp. 1-28.
Novina et al.,“siRNA-directed inhibition of HIV-1 infection”, Nature Publishing Group (NPG), 2003, Nature Medicine, vol. 8, No. 7, Jul. 2002, pp. 681-686.
Reiser et al. Nov. 2000. Development of Multigene and Regulated Lentivirus Vectors. Journal Virol. vol. 74, No. 22. 10589-10599.
Iwakuma et al. 1999. Self-inactivating Lentiviral Vectors with U3 and U5 Modifications. Virology. vol. 261, 120-132.
Gatlin et al. Jun. 2001. Long-term engraftment of nonobese diabetic/severe combined immunodeficient mice with human CD34+ cells transduced by a self-inactivating human immunodeficiency virus type I vector. Human Gene Therapy. vol. 12. 1079-1089.
Godwin et al. Oct. 1998. Detection of targeted GFP-Hox gene fusions during mouse embryogenisis. PNAS. vol. 95. 13042-10347.
Timmons et al. Oct. 1998. Specific interference by ingested dsRNA. Nature. vol. 395. 854.
Ilves et al. 1996. Retroviral Vectors designed for targeted expression of RNA polymerases III-driven transcrips: a comparative study. Gene. vol. 171. 203-208.
Junker et al. 1994. Reduction in replication of the human immunodeficiency virus type I in human T cell lines by polymerase III-driven transcription of chemeric tRNA-antisense RNA genes. Antisense Research and Development. vol. 4. 165-172.
Ogueta et al. 2001. Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector. Molecular Medicine. Vo.. 7, No. 8. 569-579.
Kafri et al. Jun. 2000. Lentiviral Vectgors: Regulated gene expression. Molecular Therapy. vol. 1., No. 6. 516-521.
Paul et al.,Effective expresion of small interfering RNA in human cells, Nature Biotechnology, Technical Report, May 2002, vol. 29.
Brummelkamp et al.,A System for Stable Expression of Short Interfering RNAs in Mammalian Cells, Science, p. 550-553, Apr. 19, 2002, vol. 296.
Caplen et al.,Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems, PNAS, p. 9742-9747, Aug. 14, 2001, vol. 98.
Paddison et al.,Short hairpin RNAs(shRNAs)induce sequence-specific silencing in mammalian cells, Genes & Development, p. 948-958, 2002.
Sui et al.,A DNA vector-based RNAi technology to supress gene expression in mammalian cells, PNAS, p. 5515-5520, Apr. 16, 2002, vol. 99.
Jacque et al.,Modulation of HIV-1 replication by RNA interface, Nature, p. 435-438, Jul. 25, 2002, vol. 418.
Lee et al.,Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells, Nature Biotechnology, Technology Report, p. 500-505, May 2002, vol. 19.
David Lawrence,RNAi could hold promise in the treatment of HIV, The Lancet, p. 207, Jun. 8, 2002, vol. 359.
Novina et al.,siRNA-directed inhibition of HIV-1 infection, Nature Medicine, p. 681-686, Jul. 2002, vol. 8.
Roger J. Pomerantz,RNA interference meets HIV-1: Will silence be golden?, Nature Medicine, p. 659-660, Jul. 2002, vol. 8.
Consiglio et al., “In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice”, Nature Medicine, Mar. 2001, pp. 310-316, vol. 7, No. 3.
De Palma et al., “In Vivo Targeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors”, Human Gene Therapy, Aug. 10, 2003, pp. 1193-1206, vol. 14.
Miyoshi et al., “Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector”, Medical Sciences, Sep. 1997, pp. 10319-10323, vol. 94.
Banerjea Akhil et al., “Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages”, Molecular Therapy : The Journal of American Society of Gene Therapy, Jul. 2003, pp. 62-71, vol. 8, No. 1.
Barton G M et al., “Retroviral delivery of small interfering RNA into primary cells”, Proceeding of the National Academy of Sciences of USA, Nov. 12, 2002, pp. 14943-14945, vol. 99, No. 23, Washington, USA.
Czauderna Frank et al., “Inducible shRNA expression for application in a prostate cancer mouse model”, Nucleic Acids Research, Nov. 1, 2003, p. e127, vol. 31, No. 21.
Devroe E. & Silver P A, “Retrovirus-delivered siRNA”, BMC Technology, Aug. 28, 2002, pp. 1-5.
Lee N S et al., “Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells”, Nature Biotechnology, May 2002, pp. 500-505, vol. 19.
Li et al., “Inhibition of HIV-1 infection by lentiviral vectors expressing pol III-promoted anti-HIV RNAs”, Molecular Therapy, Academic Press, Aug. 2003, pp. 196-206, vol. 8, No. 2, San Diego, CA, USA.
Lois Carlos et al., “Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors”, Science, Feb. 1, 2002, pp. 868-872, vol. 295, No. 5556.
Matsukura S et al., “Establishment of conditional vectors for hairpin siRNA knockdowns”, Nucleic Acids Research, Aug. 1, 2003, pp. e77-1, vol. 31, No. 15, Oxford University.
Miyagishi M. et al., “U6 promoter-driven sirnas with four uridine 3′ overhangs eff
An Dong Sung
Baltimore David
Chen Irvin S. Y.
Lois-Caballe Carlos
Qin Xiao-Feng
California Institute of Technology
Knobbe Martens Olson & Bear LLP
Zara Jane
LandOfFree
Method for expression of small antiviral RNA molecules... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for expression of small antiviral RNA molecules..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for expression of small antiviral RNA molecules... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730059